REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), dated as of April 23, 1999, is entered into by and among Generex Biotechnology Corp., an Idaho corporation, with headquarters located at 33 Harbour Square, Suite 202,...Registration Rights Agreement • July 12th, 1999 • Generex Biotechnology Corp • Pharmaceutical preparations • Illinois
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • November 12th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
Exhibit 4.19 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of February 13, 2004, by and among Generex Biotechnology Corporation, a Delaware corporation (the "Company"), and the...Registration Rights Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
AUGUST 6, 2003Stockholders' Agreement • October 29th, 2003 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 29th, 2017 • Generex Biotechnology Corp • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into on March 24, 2017 between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
BETWEENLicense Agreement • September 9th, 2003 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 3rd, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, FL 33025 (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022 (the "Buyer").
I. ASSIGNMENT AND ASSUMPTION AGREEMENT THIS AGREEMENT made as of the 1st day of October, 1996 B E T W E E N: DR. PANKAJ MODI, an individual residing in the City of Hamilton, in the Province of Ontario, (hereinafter called the "Assignor")Assignment and Assumption Agreement • February 24th, 1999 • Generex Biotechnology Corp • Pharmaceutical preparations • Ontario
COMMON STOCK PURCHASE WARRANT generex biotechnology corporationSecurity Agreement • June 25th, 2015 • Generex Biotechnology Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EXHIBIT 4.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "AGREEMENT") is made and entered into as of June 23, 2004, by and among Generex Biotechnology Corporation, a Delaware corporation (the "COMPANY"), and the investors...Registration Rights Agreement • July 14th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGERMerger Agreement • August 15th, 2003 • Generex Biotechnology Corp • Pharmaceutical preparations • Massachusetts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 25th, 2015 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 24, 2015, between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
GENEREX BIOTECHNOLOGY CORPORATION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made as of January 16, 2001 by and among Generex Biotechnology Corporation, a Delaware corporation (the "Company"), and Elan...Registration Rights Agreement • January 23rd, 2001 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
WITNESSETH:Employment Agreement • April 11th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • July 14th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
EXHIBIT 4.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of November 10, 2004, among Generex Biotechnology Corporation, a Delaware corporation (the "Company"), and the purchasers...Registration Rights Agreement • November 12th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations
Exhibit 4.10 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of February 6, 2004, by and among Generex Biotechnology Corporation, a Delaware corporation (the "Company"), and the investors...Registration Rights Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION...Securities Agreement • November 12th, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 3rd, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of June 25, 2020, by and between GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation (the "Company"), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company (together with it permitted assigns, the "Buyer"). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 6th, 2017 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March ___, 2017, between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 7th, 2020 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of August 4, 2020, by and among Generex Biotechnology Corporation, a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, Florida 33025 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").
REGISTRATION RIGHTS AGREEMENT (US) This REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of May ___, 2000, is entered into by and among Generex Biotechnology Corporation, a Delaware corporation, with headquarters located at 33 Harbour...Registration Rights Agreement • June 13th, 2000 • Generex Biotechnology Corp • Pharmaceutical preparations • Illinois
6% SECURED CONVERTIBLE DEBENTURE DUE MAY 28, 2007Convertible Security Agreement • October 16th, 2006 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
THIS DEBENTURE of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), is designated as its 6% Convertible Debenture, due May 28, 2007 (the “Debenture”).
EXHIBIT 4 PROMISSORY NOTE & AGREEMENT PRINCIPAL: $500,000 DATED: MARCH 28, 2005 INTEREST RATE: 10% MATURITY DATE: MAY 15, 2005 FOR VALUE RECEIVED, GENEREX BIOTECHNOLOGY CORPORATION (the "Borrower") hereby acknowledges itself indebted and promises to...Promissory Note • April 1st, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations
FOR VALUE RECEIVED, GENEREX BIOTECHNOLOGY CORPORATION (the "Borrower") hereby acknowledges itself indebted and promises to pay to CRANSHIRE CAPITAL, L.P. (the "Holder"), at 666 Dundee Road, Suite 1901, Northbrook, Illinois 60062 the principal sum of Five Hundred Thousand Dollars ($500,000) in lawful money of the United States of America.
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • March 1st, 2004 • Generex Biotechnology Corp • Pharmaceutical preparations • Delaware
COMMON STOCK PURCHASE WARRANT generex biotechnology corporationSecurities Agreement • March 28th, 2014 • Generex Biotechnology Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 2nd, 2008 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 31, 2008, is by and among Generex Biotechnology Corporation, a Delaware corporation with headquarters located at 33 Harbour Square, Suite 202, Toronto, Ontario, Canada (the “Company”), and the undersigned buyers (each, a “Buyer”, and collectively, the “Buyers”).
EXHIBIT 10.1.3 MEMORANDUM OF AGREEMENT THIS AGREEMENT made as of the 7th day of January, 1998, between GENEREX PHARMACEUTICALS INC., an Ontario corporation, GHI, INC. ("GHI"), a Turks and Cacos corporation, GENEREX BIOTECHNOLOGY CORPORATION, a...Memorandum of Agreement • October 29th, 2001 • Generex Biotechnology Corp • Pharmaceutical preparations • Ontario
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 16th, 2009 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated June 15, 2009, between Generex Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
ANDDevelopment and License Agreement • January 24th, 2001 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
CONFIDENTIAL Generex Biotechnology CorporationPlacement Agent Agreement • May 18th, 2009 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
CONVERTIBLE NOTE DUE MARCH ____, 2018Convertible Security Agreement • March 6th, 2017 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
THIS CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation, (the “Borrower”), having its principal place of business , 4145 North Service Road, Suite 200, Burlington, Ontario, Canada L7L 6A3, Fax: [RC], due March ___, 2018 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
COMMON STOCK PURCHASE WARRANT GENEREX BIOTECHNOLOGY CORPORATIONCommon Stock Purchase Warrant • July 11th, 2011 • Generex Biotechnology Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Date Due Payment Amount -------- -------------- -- -------- -------------- 3. Unless Investor otherwise advises the Company, the Shares, when issued, should be registered on the Company's books as follows: 4. Investor understands and agrees that: (a)...Subscription Agreement • December 14th, 1998 • Generex Biotechnology Corp
